"use strict";(self.webpackChunkparkinsons_website=self.webpackChunkparkinsons_website||[]).push([[277],{193:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,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"},"images":{"fallback":{"src":"/parkinsons-website/static/b339f4ccf324017ae71ea6301b0a396c/b1335/10_clusters_well_measured.png","srcSet":"/parkinsons-website/static/b339f4ccf324017ae71ea6301b0a396c/bfc51/10_clusters_well_measured.png 739w,\\n/parkinsons-website/static/b339f4ccf324017ae71ea6301b0a396c/de339/10_clusters_well_measured.png 1477w,\\n/parkinsons-website/static/b339f4ccf324017ae71ea6301b0a396c/b1335/10_clusters_well_measured.png 2954w","sizes":"(min-width: 2954px) 2954px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/b339f4ccf324017ae71ea6301b0a396c/11f90/10_clusters_well_measured.webp 739w,\\n/parkinsons-website/static/b339f4ccf324017ae71ea6301b0a396c/61984/10_clusters_well_measured.webp 1477w,\\n/parkinsons-website/static/b339f4ccf324017ae71ea6301b0a396c/db06c/10_clusters_well_measured.webp 2954w","type":"image/webp","sizes":"(min-width: 2954px) 2954px, 100vw"}]},"width":2954,"height":2356}')},234:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,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"},"images":{"fallback":{"src":"/parkinsons-website/static/d221df341dc02e362aa5305e8a58c1f9/70f5b/03_moca_upsit_distributions.png","srcSet":"/parkinsons-website/static/d221df341dc02e362aa5305e8a58c1f9/4c8f6/03_moca_upsit_distributions.png 1043w,\\n/parkinsons-website/static/d221df341dc02e362aa5305e8a58c1f9/fefb9/03_moca_upsit_distributions.png 2085w,\\n/parkinsons-website/static/d221df341dc02e362aa5305e8a58c1f9/70f5b/03_moca_upsit_distributions.png 4170w","sizes":"(min-width: 4170px) 4170px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/d221df341dc02e362aa5305e8a58c1f9/c3d1e/03_moca_upsit_distributions.webp 1043w,\\n/parkinsons-website/static/d221df341dc02e362aa5305e8a58c1f9/99386/03_moca_upsit_distributions.webp 2085w,\\n/parkinsons-website/static/d221df341dc02e362aa5305e8a58c1f9/b5cee/03_moca_upsit_distributions.webp 4170w","type":"image/webp","sizes":"(min-width: 4170px) 4170px, 100vw"}]},"width":4170,"height":1770}')},2198:function(e,t,a){a.r(t),a.d(t,{default:function(){return r}});var i=a(6540),n=a(2002),s=a(2532);function r(){return i.createElement(n.A,null,i.createElement("div",{className:"page-container home-page"},i.createElement("section",{className:"hero-section"},i.createElement("div",{className:"hero-text"},i.createElement("h1",null,"Comprehensive Parkinson's Disease Mechanism Inference Analysis"),i.createElement("p",null,"This project documents a mechanism-based computational framework for Parkinson's disease analysis, analyzing data across two major cohorts: the Parkinson's Progression Markers Initiative (PPMI, n=14,473 patients) and the LRRK2 Consortium (n=2,958 individuals)."),i.createElement("p",{className:"hero-subtext"},"The goal was to shift the paradigm from classifying patients merely by symptoms to inferring underlying biological pathway dysfunctions."))),i.createElement("section",{className:"section"},i.createElement("h2",{className:"section-title"},"I. Foundational Methodology and Research Rigor"),i.createElement("p",null,"Our methodology focused on mechanism inference."),i.createElement("h3",null,"Paradigm Shift to Mechanisms"),i.createElement("p",null,'We moved beyond traditional symptom-based classification (e.g., "tremor-dominant PD") to identify the specific biological pathway dysfunctions (such as dopaminergic degeneration or LRRK2 kinase activity) causing observed clinical manifestations.'),i.createElement("h3",null,"Biological Pathways Analyzed"),i.createElement("p",null,"The analysis covered 5 major categories implicated in PD pathogenesis:"),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,"Pathway 01: Dopaminergic Degeneration & Motor Control (Nigrostriatal tract)"),i.createElement("li",null,"Pathway 02: Genetic & Molecular Mechanisms (LRRK2 kinase, α-Synuclein pathology)"),i.createElement("li",null,"Pathway 03: Cholinergic & Cognitive Control (Olfaction, cognition, sleep disorders)"),i.createElement("li",null,"Pathway 06: Gait Dynamics & Wearable Sensors (Objective kinematic measures)"),i.createElement("li",null,"Pathway 08: Cross-Pathway Integration (Multimodal characterization)")),i.createElement("h3",null,"Advanced Clustering Technique"),i.createElement("p",null,"We employed a Bayesian Gaussian Mixture Model (B-GMM) with a Dirichlet Process Prior to automatically determine the optimal number of patient subgroups (phenotypes) based on statistical criteria, such as the lowest Bayesian Information Criterion (BIC)."),i.createElement("h3",null,"Compliance"),i.createElement("p",null,"We maintained complete data integrity by strictly enforcing NO data imputation; only actual measured values were analyzed. All 36 evidence-based research claims are supported by complete code-to-result traceability.")),i.createElement("section",{className:"section"},i.createElement("h2",{className:"section-title"},"II. Major Verified Findings (Tier 1 Discoveries)"),i.createElement("p",null,"The analysis generated 36 verified claims. The following are the most clinically significant discoveries:"),i.createElement("h3",null,"1. Genetic Risk Quantification: LRRK2 G2019S"),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/02_lrrk2_penetrance_analysis.png",alt:"LRRK2 Penetrance Analysis",placeholder:"blurred",__imageData:a(4866)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 1: LRRK2 Penetrance Analysis demonstrating difference in PD prevalence between LRRK2 carriers and non-carriers")),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,i.createElement("strong",null,"Finding:")," The LRRK2 G2019S mutation confers a 1.89-fold increased risk for Parkinson's disease in the LRRK2 Consortium cohort (n=2,958)"),i.createElement("li",null,i.createElement("strong",null,"Supporting Evidence:")," 49.7% of LRRK2-positive carriers developed PD (805/1,620), compared to 26.3% of LRRK2-negative non-carriers (352/1,338)"),i.createElement("li",null,i.createElement("strong",null,"Statistical Proof:")," The association is highly significant (χ² = 167.263, p < 0.001)")),i.createElement("h3",null,"2. Motor Phenotype Heterogeneity"),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/01_motor_phenotype_clusters.png",alt:"Motor Phenotype Clusters (PCA)",placeholder:"blurred",__imageData:a(8850)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 2: Motor Phenotype Clusters - 4,166 patients plotted in 2D space (PCA) with 71.7% variance preserved, visually confirming separation of 5 phenotypes")),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,i.createElement("strong",null,"Finding:")," Unsupervised clustering of 4,166 baseline UPDRS-III motor assessments identified 5 distinct motor phenotypes in PD patients"),i.createElement("li",null,i.createElement("strong",null,"Supporting Evidence:")," The clusters demonstrated moderate-good separation validated by a Silhouette Score of 0.535"),i.createElement("li",null,i.createElement("strong",null,"Clinical Profile:")," The phenotypes showed a clear severity gradient, ranging from the largest cluster (47.4%, Minimal/Early-stage, mean UPDRS=2.49) to the smallest, most severely impaired cluster (3.1%, Severe impairment, mean UPDRS=34.61)")),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/07_motor_phenotype_profiles.png",alt:"Motor Phenotype Profiles",placeholder:"blurred",__imageData:a(5508)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 3: Motor Phenotype Profiles showing mean subscale scores by phenotype")),i.createElement("h3",null,"3. Prodromal Olfactory Dysfunction"),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/03_moca_upsit_distributions.png",alt:"MoCA & UPSIT Distributions",placeholder:"blurred",__imageData:a(234)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 4: MoCA & UPSIT Distributions highlighting 50.2% hyposmia prevalence")),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,i.createElement("strong",null,"Finding:")," 50.2% of the assessed cohort (n=5,122) exhibited olfactory dysfunction (hyposmia, UPSIT score < 25)"),i.createElement("li",null,i.createElement("strong",null,"Mechanism Inference:")," This high prevalence confirms hyposmia as a major prodromal marker for PD, indicating α-synuclein pathology has reached the olfactory bulb (Braak Stage 1-2) before substantial dopaminergic neuron death occurs"))),i.createElement("section",{className:"section"},i.createElement("h2",{className:"section-title"},"III. Key Findings Across Biological Pathways"),i.createElement("h3",null,"Pathway 01: Dopaminergic & Motor Control"),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,i.createElement("strong",null,"LRRK2 and Motor Severity:")," LRRK2-positive carriers (n=1,507) exhibit 49% worse motor severity (mean UPDRS3 = 12.47) compared to LRRK2-negative non-carriers (mean UPDRS3 = 8.36, p < 0.001, Cohen's d = 0.304)"),i.createElement("li",null,i.createElement("strong",null,"Gait-Motor Correlation:")," Objectively measured gait speed (SP_U) negatively correlates with clinically assessed motor severity (UPDRS-III total, Spearman r = -0.301, p = 0.000079, n=166)")),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/06_gait_motor_stratification.png",alt:"Gait-Motor Stratification",placeholder:"blurred",__imageData:a(4652)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 5: Gait Speed vs Motor Severity showing negative correlation")),i.createElement("h3",null,"Pathway 03: Cholinergic & Cognitive Control"),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,i.createElement("strong",null,"RBD Prevalence:")," 37.5% of assessed patients (n=1,548) were RBD-positive, indicating specific brainstem α-synucleinopathy affecting REM sleep control"),i.createElement("li",null,i.createElement("strong",null,"Cognitive Decline:")," 25.9% of patients (n=13,835) scored below the MCI threshold (MoCA < 26), reflecting degeneration in the cholinergic basal forebrain"),i.createElement("li",null,i.createElement("strong",null,"Multimodal Correlation:")," Positive correlation between MoCA cognitive scores and UPSIT olfactory scores (r = 0.165, p < 0.001, n=5,063), supporting the hypothesis of shared α-synuclein pathological spread")),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/04_rbd_prevalence.png",alt:"RBD Prevalence",placeholder:"blurred",__imageData:a(4080)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 6: RBD Prevalence showing proportion of RBD-positive individuals")),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/08_multimodal_correlations.png",alt:"Cognitive-Olfactory Correlation",placeholder:"blurred",__imageData:a(7547)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 7: Cognitive-Olfactory Correlation (r=0.165, p<0.001)")),i.createElement("h3",null,"Pathway 06: Gait Dynamics & Wearable Sensors"),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,i.createElement("strong",null,"Dual-Task Cost:")," Gait speed significantly degrades under cognitive load with a mean dual-task cost of 14.87% (t = 14.984, p < 0.001, n=172), evidencing cognitive-motor network integration failure"),i.createElement("li",null,i.createElement("strong",null,"Arm Swing Asymmetry:")," Using IMU sensors, 27.0% of patients (n=178) exhibited clinically significant asymmetry (>20%), supporting lateralized dopaminergic neuron loss mechanism"),i.createElement("li",null,i.createElement("strong",null,"Mobility Impairment:")," 29.0% of patients (n=186) were classified as mobility impaired (TUG duration > 12 seconds)")),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/05_arm_swing_asymmetry.png",alt:"Arm Swing Asymmetry Distribution",placeholder:"blurred",__imageData:a(6639)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 8: Arm Swing Asymmetry Distribution highlighting 20% clinical threshold")),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/09_tug_performance.png",alt:"TUG Performance Distribution",placeholder:"blurred",__imageData:a(5315)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 9: TUG Performance Distribution (n=186)"))),i.createElement("section",{className:"section"},i.createElement("h2",{className:"section-title"},"IV. Multimodal Biomarkers and Clinical Translation"),i.createElement("p",null,"The project's ultimate objective is enabling precision medicine by integrating multiple findings."),i.createElement("h3",null,"Objective Biomarker Validation"),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,"Phospho-S1292-LRRK2 in urinary exosomes (n=884) documented as a pharmacodynamic marker for LRRK2 inhibitor therapy"),i.createElement("li",null,"CSF α-Synuclein Seed Amplification Assay (CSFSAA) status assessed in 145 samples, useful for differentiating PD from atypical parkinsonisms")),i.createElement("h3",null,"Clinical Translation Readiness"),i.createElement("p",null,"The quantified findings directly support immediate clinical applications:"),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,i.createElement("strong",null,"Genetic Testing:")," Precise risk quantification (1.89×) informs LRRK2 screening guidelines"),i.createElement("li",null,i.createElement("strong",null,"Prodromal Screening:")," High prevalence of hyposmia (50.2%) and RBD (37.5%) provides clear targets for early detection and intervention"),i.createElement("li",null,i.createElement("strong",null,"Motor Phenotyping:")," The 5 identified motor subtypes enable selection of stratified, pathway-specific treatments")),i.createElement("div",{className:"progressive-ai-image"},i.createElement(s.S,{src:"../images/10_clusters_well_measured.png",alt:"Additional Clustering View",placeholder:"blurred",__imageData:a(193)}),i.createElement("p",{style:{fontSize:"0.9rem",color:"#726657",marginTop:"0.5rem"}},"Figure 10: Additional clustering visualization for Dopaminergic Pathway analysis"))),i.createElement("section",{className:"section"},i.createElement("h2",{className:"section-title"},"Complete Claims Summary"),i.createElement("p",null,"This comprehensive analysis documents 36 evidence-based research claims organized across five major biological pathway categories:"),i.createElement("h3",null,"Pathway 01: Dopaminergic Degeneration & Motor Control (15 Claims)"),i.createElement("p",null,"Including motor phenotype identification, LRRK2 motor severity effects, gait-motor correlations, and longitudinal tracking capabilities"),i.createElement("h3",null,"Pathway 02: Genetic & Molecular Mechanisms (4 Claims)"),i.createElement("p",null,"Covering LRRK2 genetic risk quantification, phospho-LRRK2 biomarkers, CSFSAA status assessment, and α-synuclein modulation"),i.createElement("h3",null,"Pathway 03: Cholinergic & Cognitive Control (10 Claims)"),i.createElement("p",null,"Addressing cognitive impairment prevalence, olfactory dysfunction, RBD prevalence, dual-task costs, and autonomic dysfunction"),i.createElement("h3",null,"Pathway 06: Gait Dynamics & Wearable Sensors (4 Claims)"),i.createElement("p",null,"Quantifying arm swing asymmetry, stride time variability, TUG performance, and dual-task degradation"),i.createElement("h3",null,"Pathway 08: Cross-Pathway Integration (3 Claims)"),i.createElement("p",null,"Synthesizing cognitive-olfactory correlations, multimodal cohort characterization, and LRRK2+ multi-phenotype profiles")),i.createElement("section",{className:"section final-callout"},i.createElement("h2",{className:"section-title"},"Clinical Impact"),i.createElement("p",null,"This mechanism-based computational framework shifts PD analysis from symptom classification to biological pathway inference, enabling:"),i.createElement("ul",{className:"tight-list"},i.createElement("li",null,"Precise genetic risk stratification for clinical decision-making"),i.createElement("li",null,"Early detection through validated prodromal markers"),i.createElement("li",null,"Personalized treatment strategies based on motor phenotype classification"),i.createElement("li",null,"Objective, quantitative biomarkers for remote monitoring and clinical trial enrichment")))))}},4080:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,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"},"images":{"fallback":{"src":"/parkinsons-website/static/4eea1f2d0cbcfa0008006c22f3c0ec79/d2ef3/04_rbd_prevalence.png","srcSet":"/parkinsons-website/static/4eea1f2d0cbcfa0008006c22f3c0ec79/68898/04_rbd_prevalence.png 422w,\\n/parkinsons-website/static/4eea1f2d0cbcfa0008006c22f3c0ec79/8c7f7/04_rbd_prevalence.png 843w,\\n/parkinsons-website/static/4eea1f2d0cbcfa0008006c22f3c0ec79/d2ef3/04_rbd_prevalence.png 1686w","sizes":"(min-width: 1686px) 1686px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/4eea1f2d0cbcfa0008006c22f3c0ec79/4ac61/04_rbd_prevalence.webp 422w,\\n/parkinsons-website/static/4eea1f2d0cbcfa0008006c22f3c0ec79/3274e/04_rbd_prevalence.webp 843w,\\n/parkinsons-website/static/4eea1f2d0cbcfa0008006c22f3c0ec79/636a6/04_rbd_prevalence.webp 1686w","type":"image/webp","sizes":"(min-width: 1686px) 1686px, 100vw"}]},"width":1686,"height":1769}')},4652:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAICAYAAAD5nd/tAAAACXBIWXMAAC4jAAAuIwF4pT92AAABEklEQVR42m1S246FMAj0/79S30x0c7T2Sqksg61nH7YJoS0wzNBOrTWB3fct67rKsiwyz7P5bdsEC7GRx8yy7/ubBzuOw3JgExEJUX1B/zPEaq0Glgu9uW+NNq0aw3kKMcoVsxQFrZUlaUHlL2ssA8rZzqXyGyNt0nrTYqSUoXNO9tMbaEhFTp86KAtrIVYpRULwVuAz2b3tE5mHxVIfyZ/PIT8KeIYkxxXFqQcwG4tmcgB4XZfduZTNw86YDASKXHr2U1TJ6JC1A5hRZzZYQDXml3rBX8mZ2DxywdwAIW0Mn/p+DHgAcn+U1rjPqvW5PSA3JCtgM8D+esO89yYPzMcdch7AJvgV8CEE+z54LJyHgl/eGXNXM+3ZJAAAAABJRU5ErkJggg=="},"images":{"fallback":{"src":"/parkinsons-website/static/cff34b88558f29677333c20b9c287837/c34b0/06_gait_motor_stratification.png","srcSet":"/parkinsons-website/static/cff34b88558f29677333c20b9c287837/86345/06_gait_motor_stratification.png 1039w,\\n/parkinsons-website/static/cff34b88558f29677333c20b9c287837/5d587/06_gait_motor_stratification.png 2078w,\\n/parkinsons-website/static/cff34b88558f29677333c20b9c287837/c34b0/06_gait_motor_stratification.png 4156w","sizes":"(min-width: 4156px) 4156px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/cff34b88558f29677333c20b9c287837/13ec1/06_gait_motor_stratification.webp 1039w,\\n/parkinsons-website/static/cff34b88558f29677333c20b9c287837/3c0c0/06_gait_motor_stratification.webp 2078w,\\n/parkinsons-website/static/cff34b88558f29677333c20b9c287837/5700f/06_gait_motor_stratification.webp 4156w","type":"image/webp","sizes":"(min-width: 4156px) 4156px, 100vw"}]},"width":4156,"height":1704.0000000000002}')},4866:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,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"},"images":{"fallback":{"src":"/parkinsons-website/static/cedfbb690489b603b245ed75a413d0e1/e277a/02_lrrk2_penetrance_analysis.png","srcSet":"/parkinsons-website/static/cedfbb690489b603b245ed75a413d0e1/c495a/02_lrrk2_penetrance_analysis.png 1039w,\\n/parkinsons-website/static/cedfbb690489b603b245ed75a413d0e1/e337e/02_lrrk2_penetrance_analysis.png 2078w,\\n/parkinsons-website/static/cedfbb690489b603b245ed75a413d0e1/e277a/02_lrrk2_penetrance_analysis.png 4156w","sizes":"(min-width: 4156px) 4156px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/cedfbb690489b603b245ed75a413d0e1/3afb9/02_lrrk2_penetrance_analysis.webp 1039w,\\n/parkinsons-website/static/cedfbb690489b603b245ed75a413d0e1/3c5bd/02_lrrk2_penetrance_analysis.webp 2078w,\\n/parkinsons-website/static/cedfbb690489b603b245ed75a413d0e1/6a385/02_lrrk2_penetrance_analysis.webp 4156w","type":"image/webp","sizes":"(min-width: 4156px) 4156px, 100vw"}]},"width":4156,"height":1756}')},5315:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,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"},"images":{"fallback":{"src":"/parkinsons-website/static/870f3ff346592653ea340df5010013a0/2ecb3/09_tug_performance.png","srcSet":"/parkinsons-website/static/870f3ff346592653ea340df5010013a0/67aa3/09_tug_performance.png 743w,\\n/parkinsons-website/static/870f3ff346592653ea340df5010013a0/d2f4f/09_tug_performance.png 1485w,\\n/parkinsons-website/static/870f3ff346592653ea340df5010013a0/2ecb3/09_tug_performance.png 2970w","sizes":"(min-width: 2970px) 2970px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/870f3ff346592653ea340df5010013a0/b8bb9/09_tug_performance.webp 743w,\\n/parkinsons-website/static/870f3ff346592653ea340df5010013a0/0fe15/09_tug_performance.webp 1485w,\\n/parkinsons-website/static/870f3ff346592653ea340df5010013a0/d9bc6/09_tug_performance.webp 2970w","type":"image/webp","sizes":"(min-width: 2970px) 2970px, 100vw"}]},"width":2970,"height":1770}')},5508:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,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"},"images":{"fallback":{"src":"/parkinsons-website/static/fe57e4cb4080f64a6654f194372ad52c/6f2d5/07_motor_phenotype_profiles.png","srcSet":"/parkinsons-website/static/fe57e4cb4080f64a6654f194372ad52c/f292f/07_motor_phenotype_profiles.png 739w,\\n/parkinsons-website/static/fe57e4cb4080f64a6654f194372ad52c/48ea4/07_motor_phenotype_profiles.png 1478w,\\n/parkinsons-website/static/fe57e4cb4080f64a6654f194372ad52c/6f2d5/07_motor_phenotype_profiles.png 2956w","sizes":"(min-width: 2956px) 2956px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/fe57e4cb4080f64a6654f194372ad52c/79c66/07_motor_phenotype_profiles.webp 739w,\\n/parkinsons-website/static/fe57e4cb4080f64a6654f194372ad52c/e0ea8/07_motor_phenotype_profiles.webp 1478w,\\n/parkinsons-website/static/fe57e4cb4080f64a6654f194372ad52c/0d763/07_motor_phenotype_profiles.webp 2956w","type":"image/webp","sizes":"(min-width: 2956px) 2956px, 100vw"}]},"width":2956,"height":1756}')},6639:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,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"},"images":{"fallback":{"src":"/parkinsons-website/static/4f733b5fe17d21db822349c1571c5d42/2ecb3/05_arm_swing_asymmetry.png","srcSet":"/parkinsons-website/static/4f733b5fe17d21db822349c1571c5d42/67aa3/05_arm_swing_asymmetry.png 743w,\\n/parkinsons-website/static/4f733b5fe17d21db822349c1571c5d42/d2f4f/05_arm_swing_asymmetry.png 1485w,\\n/parkinsons-website/static/4f733b5fe17d21db822349c1571c5d42/2ecb3/05_arm_swing_asymmetry.png 2970w","sizes":"(min-width: 2970px) 2970px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/4f733b5fe17d21db822349c1571c5d42/b8bb9/05_arm_swing_asymmetry.webp 743w,\\n/parkinsons-website/static/4f733b5fe17d21db822349c1571c5d42/0fe15/05_arm_swing_asymmetry.webp 1485w,\\n/parkinsons-website/static/4f733b5fe17d21db822349c1571c5d42/d9bc6/05_arm_swing_asymmetry.webp 2970w","type":"image/webp","sizes":"(min-width: 2970px) 2970px, 100vw"}]},"width":2970,"height":1770}')},7547:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAICAYAAAD5nd/tAAAACXBIWXMAAC4jAAAuIwF4pT92AAABHklEQVR42l2RiW7EIAxE8/+/WVU5VjkgIZxmajuwkYoyMgvjt7YZaq3oWtcV0zRhmWeM4whjLIjPiUglK4SAfd9xHMcTWYb3JWdlDLlt+NNFVHHHDBcSxs3iYxxCynh9zdgLkT9LESV4zVWgVtAr4XgzzDiP0wWcd0BkTykFVTkCogckuXyeLgO/Lfp7uK4LharSFcoqbE6F4GPSSlPiyD4tTMAC45jdiewd3PwL/xn1TIG9VZFUUBiWWQKWGBlsrRWcwsRDOSGajauz8OsCN/1o5UNmammmdzxVcpGytPm0qC33Gba2qfBcifP9rdJHoS+s0dp62n/v/j+K7gXYRtDvhqfFohJ4jBHOOUSeW26PIep78UgUn4xLz5vk7g/FWHTizgmL0AAAAABJRU5ErkJggg=="},"images":{"fallback":{"src":"/parkinsons-website/static/1c6c5c9a15fe48c9f8cd5fb6fce70c4f/70f5b/08_multimodal_correlations.png","srcSet":"/parkinsons-website/static/1c6c5c9a15fe48c9f8cd5fb6fce70c4f/4c8f6/08_multimodal_correlations.png 1043w,\\n/parkinsons-website/static/1c6c5c9a15fe48c9f8cd5fb6fce70c4f/fefb9/08_multimodal_correlations.png 2085w,\\n/parkinsons-website/static/1c6c5c9a15fe48c9f8cd5fb6fce70c4f/70f5b/08_multimodal_correlations.png 4170w","sizes":"(min-width: 4170px) 4170px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/1c6c5c9a15fe48c9f8cd5fb6fce70c4f/c3d1e/08_multimodal_correlations.webp 1043w,\\n/parkinsons-website/static/1c6c5c9a15fe48c9f8cd5fb6fce70c4f/99386/08_multimodal_correlations.webp 2085w,\\n/parkinsons-website/static/1c6c5c9a15fe48c9f8cd5fb6fce70c4f/b5cee/08_multimodal_correlations.webp 4170w","type":"image/webp","sizes":"(min-width: 4170px) 4170px, 100vw"}]},"width":4170,"height":1770}')},8850:function(e){e.exports=JSON.parse('{"layout":"constrained","placeholder":{"fallback":"data:image/png;base64,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"},"images":{"fallback":{"src":"/parkinsons-website/static/a47787abb03510ae897c78dce1c29189/fea59/01_motor_phenotype_clusters.png","srcSet":"/parkinsons-website/static/a47787abb03510ae897c78dce1c29189/bfc51/01_motor_phenotype_clusters.png 739w,\\n/parkinsons-website/static/a47787abb03510ae897c78dce1c29189/9cc6d/01_motor_phenotype_clusters.png 1478w,\\n/parkinsons-website/static/a47787abb03510ae897c78dce1c29189/fea59/01_motor_phenotype_clusters.png 2956w","sizes":"(min-width: 2956px) 2956px, 100vw"},"sources":[{"srcSet":"/parkinsons-website/static/a47787abb03510ae897c78dce1c29189/11f90/01_motor_phenotype_clusters.webp 739w,\\n/parkinsons-website/static/a47787abb03510ae897c78dce1c29189/bcbc2/01_motor_phenotype_clusters.webp 1478w,\\n/parkinsons-website/static/a47787abb03510ae897c78dce1c29189/2c56f/01_motor_phenotype_clusters.webp 2956w","type":"image/webp","sizes":"(min-width: 2956px) 2956px, 100vw"}]},"width":2956,"height":2356}')}}]);
//# sourceMappingURL=component---src-pages-silo-2-js-a746b34d0799ac592289.js.map